Peripheral T-Cell Lymphoma : Moving Toward Targeted Therapies - 21/06/19

Doi : 10.1016/j.hoc.2019.04.002

Samuel Y. Ng, MD, PhD ^⁎ , Eric D. Jacobsen, MD
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA

^∗Corresponding author.

Resumen

Therapeutic advances for peripheral T-cell non-Hodgkin lymphoma (PTCL) have lagged behind their B-cell NHL counterparts in part because novel agents to treat PTCL have been developed empirically. The recent clinical success of brentuximab-vedotin suggests that novel therapies for PTCL can significantly improve outcomes when properly targeted. Aberrancies in T-cell receptor, Jak/STAT, and DNA methylation pathways play critical roles in T-NHL pathogenesis based on genomic studies and preclinical experimental validation. New strategies targeting these pathways in patients with PTCL are underway, and this clinical trial experience will possibly contribute to additional improvements in outcome for patients with these diseases.

El texto completo de este artículo está disponible en PDF.

Keywords : T-cell lymphoma, Targeted therapy, Jak/STAT pathway, DNA methylation

Esquema

Key points

Introduction

Summary and rationale for current treatment paradigms

FDA-approved agents for the treatment of Peripheral T-cell lymphoma

Other agents with activity in T-cell lymphomas

Molecular advances in understanding Peripheral T-cell lymphomas

Recent clinical findings for targeted therapy in Peripheral T-cell lymphomas

Immunotherapy in Peripheral T-cell lymphomas

Future approaches to treatment of Peripheral T-cell lymphomas

Disclosure Statement: Dr S.Y. Ng has nothing to disclose. Dr E.D. Jacobsen receives research funding from Celgene, Merck, Janssen and honoraria from Bayer, Seattle Genetics.